W used in the treatment of rheumatoid arthritis define where a patient or even an individual joint is in this process or how best to proceed with therapy. The (RA) for over 40 yr, the controversy over the appropriate use of corticosteroids remains. What scientific treatment of RA still remains a method of trial and error with the rheumatologist constantly working to data exist, either pro or con, provide fuel for heated discussions. In spite of concerns for long-term safety provide the best clinical response in each patient. Even with recent biological and combination therapies, and limited data on disease modification, a recent international multicentre study found that~50% of efficacy only approaches 50-70% in 60% of patients [6, 7] . True drug-free remissions occur in <10% of all patients with RA treated by rheumatologists, whether in an academic or private practice setting, are patients with seropositive disease. Corticosteroids provide an important intervention, especially when used on low-dose (<10 mg/day) prednisone [1] . In fact, at a recent consensus conference, it was concluded that in addition to other agents. Alone, the dosage needed is too high to be safe and patients ultimately become low-dose steroids in addition to methotrexate should be the foundation for combination therapy in aggressteroid dependent. However, in combination with a DMARD, a lower dose can be used for longer periods sive RA [2] . Therefore, from a practical standpoint, while corticosteroids are a mainstay of therapy, the of time. The study reported here, as well as others, support this [4, 5] . scientific data supporting their use are limited.
In addition to baseline therapy in patients with Rheumatologists have known for a long time that corticosteroids are effective and have tried hard to use severe disease, corticosteroids are used during flares and as a bridge during changes in disease-modifying them safely. The studies reported here suggest that we are doing better. However, given the course of RA anti-rheumatic drug (DMARD) therapy. In general, this means that when patients are not doing well, and the present mixtures of agents used, it is highly unlikely that a 'perfect' study will ever be performed corticosteroid therapy is initiated and, in many situations, continued for extended periods. The major to prove the effects of corticosteroids. It is likely, however, that they will kindle many studies and conchange in the use of corticosteroids appears to be the dosage, with most rheumatologists recognizing the tinue to provide excellent discussions for a long time.
There may be a lot to learn by looking at the various deleterious effects of chronic 'high' doses. However, the definition of high-vs low-dose corticosteroids conmechanisms of action of corticosteroids and the outcomes of the studies reviewed by Jansen. While tinues to be a major area of discussion. Even in the article by Jansen et al.
[3], low doses are described as rheumatologists are excited about the new agents destined to be released in the next few years, including both less than 15 mg/day and 10 mg/day. The article by Hickling et al.
[4] supports 7.5 mg/day as disease the tumour necrosis factor ( TNF ) antagonists, the interleukin-1 antagonists and the COX-2-selective modifying and the work by Boers et al.
[5] supports these findings. This is a critical issue as other studies agents, corticosteroids provide all of these activities and then some. A single pulse of methylprednisolone suggest that doses <7.5 mg/day are not as efficacious. However, most rheumatologists have patients who are is very effective at inhibiting TNF down to the level of synovial expression. Indeed, like reported TNF very stable on <5 mg/day in combination with a DMARD. It is common practical knowledge that antagonist responses, corticosteroid therapy results in a more consistent clinical response when used in compatients with RA note flares with changes of as little as 1 mg/day. Long-term studies evaluating dose, especibination with DMARDs. When used long term, it appears that they have disease-modifying properties. ally in combination with a DMARD, are needed.
While RA is a disease that affects 1% of nearly all Given the reported costs of some of these newer agents, one must question whether they will truly add anything populations, worldwide and associated with a specific HLA class II epitope, it is a heterogeneous disease to the therapy of RA. The lessons from corticosteroid therapy support the need for long-term studies of these both in its course and response to anti-rheumatic therapy. Present theories suggest that affected patients newer agents, especially addressing safety and disease modification. are exposed to the arthritogenic agent months, and potentially years, in advance of clinical presentation.
The long-term use of high-dose corticosteroids leads to a variety of significant side-effects, most of which Therefore, even at the time of clinical diagnosis, RA is already a multicellular process involving lymphowe have all seen in the clinics. Most of these occur at doses >10 mg/day and rarely at doses <5 mg/day. cytes, macrophages, endothelial cells and synovial fibroblasts, to name a few. In addition, we know that While serious infections are a major issue, they are far less frequent at the lower doses. Similarly, osteoporosis there are hormonal issues including gender specificity and the HPA axis. Unfortunately, it is impossible to is less at lower doses. Recent data support the use of with long-term problems.
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In conclusion, the discussion on the efficacy and 
FROM CRITICISM TO CREATIVITY: THE GENESIS OF THE ARC/BSR CLINICAL TRIALS GROUP
M of us suffer the pressures of working in isolation, research on a multicentre basis, with a national direction. The ultimate objective is to enable the clinicians and regularly contemplate the nature of the evidence which drives our clinical practice. The bench-mark for throughout the UK to network together and participate in clinical trials relevant to the spectrum of evaluation of management strategies in clinical medicine is the randomized controlled trial, and ideas for rheumatic diseases both common and rare. The product of these deliberations was the ARC/BSR Clinical such trials regularly arise during busy clinical practice. However, the translation from these ideas to the design, Trials Group, which has now been 'pump-primed' with a £1.5 million budget from the ARC. execution, analysis and publication of the finished product is a difficult task, and one where the busy
We believe that the current membership of the group incorporates the appropriate expertise, including clinician is limited by lack of time, resources, and a supporting infrastructure-a view eloquently expressed clinical trials methodology, health services research and rheumatology, in order to set up and oversee by Professor Ian Haslock in a letter to the British Journal of Rheumatology [1] . the venture. All members of the BSR will shortly receive a letter This cri de coeur initiated a series of debates within the Research Subcommittee and Scientific Cooutlining the purpose of the group and how it will facilitate multicentre trials. A request will be made for ordinating Committee of the Arthritis Research Campaign, leading to the formation of an ARC Think members to define two key questions which need to be addressed in rheumatological practice and to provide Tank on clinical trials. This group took advice from many sources, including members of the Medical an outline proposal giving brief details of the objectives, methodology and background. Proposals received Research Council who have considerable expertise in multicentred randomized trials and now an accepted will be prioritized using a Delphi approach (the postal request for questions followed by an analysis of the base for much of haematological and oncological practice.
complete response after anonymization), followed by a nominal group process involving the ARC/BSR In recognition of the difficulties encountered by the clinical rheumatologists in the UK, a combined Clinical Trials Committee in which an explicit ranking of proposals will be undertaken. It is envisaged that response from the ARC and BSR led to the evolution of a structure of support incorporating the skills of 2-3 programmes will be supported during 1999. When the programmes have been identified, the group will relevant professional bodies to promote clinical provide active support facilitating the integration of promote the highest quality of care to rheumatology patients. investigators and defining key investigators who will drive each proposal. The BSR in particular will assist relevant research in our speciality. We encourage you R to take part in this important venture, which we believe will benefit the busy clinician and our speciality,
